An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ...
Briganti and colleagues concluded that, together with the main PROTEUS study, the substudy supports 1-year perioperative apalutamide plus ADT as a treatment option for patients with high-risk ...
Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy (ADT), given ...
Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is safe and effective for patients with ...
Prostate cancer treatments carry different risks. Dr. Fernando Bianco argues for informed decisions that balance cancer ...
Mr Sanjith Gnanappiragasam, Consultant Urological Surgeon at King’s, said: “Delivering this type of treatment within 15 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results